-
公开(公告)号：US20120215109A1
公开(公告)日：2012-08-23
申请号：US13505140
申请日：2010-11-10
申请人： Naoto Kubota , Norihiro Koizumi , Hongen Liao , Takaharu Asano , Kazuhito Yuhashi , Mamoru Mitsuishi , Shin Ohnishi , Takashi Mochizuki , Ichiro Sakuma , Takashi Kadowaki
发明人： Naoto Kubota , Norihiro Koizumi , Hongen Liao , Takaharu Asano , Kazuhito Yuhashi , Mamoru Mitsuishi , Shin Ohnishi , Takashi Mochizuki , Ichiro Sakuma , Takashi Kadowaki
CPC分类号： A61B8/5223 , A61B5/4872 , A61B8/085 , A61B8/0858 , A61B8/14 , A61B8/4209 , A61B8/4227
摘要： When an amount of visceral fat is measured using ultrasonic waves during medical examination of metabolic syndrome, three contact positions are defined on the surface of the abdominal region, and three distances inside the living body are measured by bringing a probe into contact with the surface of the abdominal region at the contact positions. Specifically, three measurement paths having a starting point at the center of the descending aorta are set, and the distances from the center to a surface of the fat layer adjacent to the surface of the body (inner surface of the subcutaneous layer) in the measurement paths are observed. An approximate area of a visceral fat region can be determined from the three distances and two angles defined by the three measurement paths, and an index value is calculated on the basis of the area. A probe holder having three holding portions is desirably used.
摘要翻译： 当在代谢综合征的体格检查期间使用超声波测量内脏脂肪的量时，在腹部区域的表面上限定三个接触位置，并且通过使探针与表面接触来测量活体内的三个距离 在接触位置的腹部区域。 具体而言，设定在下降主动脉中心具有起点的三个测量路径，并且测量与测量中的与身体表面（皮下层的内表面）相邻的脂肪层的中心到表面的距离 观察路径。 可以从由三个测量路径定义的三个距离和两个角度确定内脏脂肪区域的近似区域，并且基于面积计算指数值。 期望使用具有三个保持部的探针保持器。
-
公开(公告)号：US07419955B2
公开(公告)日：2008-09-02
申请号：US10514715
申请日：2003-05-26
申请人： Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
发明人： Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
IPC分类号： A61K38/00
CPC分类号： A61K38/2264 , A61K48/00
摘要： A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.
摘要翻译： 清道夫受体A表达下调和用于预防或治疗动脉硬化的药物，其含有脂联素，脂联素或编码结构域或脂联素的基因的C-末端球状结构域作为活性成分。 根据本发明，提供能够直接防止内膜增厚的预防或治疗剂，其构成动脉硬化的基本特征。 通过降低动脉壁中清道夫受体A的表达水平并防止巨噬细胞中的脂质积聚，可以通过阻止动脉硬化的发生和发展来实现该效果。
-
公开(公告)号：US20060166873A1
公开(公告)日：2006-07-27
申请号：US10514715
申请日：2003-05-26
申请人： Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
发明人： Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
CPC分类号： A61K38/2264 , A61K48/00
摘要： A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.
摘要翻译： 清道夫受体A表达下调和用于预防或治疗动脉硬化的药物，其含有脂联素，脂联素或编码结构域或脂联素的基因的C-末端球状结构域作为活性成分。 根据本发明，提供能够直接防止内膜增厚的预防或治疗剂，其构成动脉硬化的基本特征。 通过降低动脉壁中清道夫受体A的表达水平并防止巨噬细胞中的脂质积聚，可以通过阻止动脉硬化的发生和发展来实现该效果。
-
公开(公告)号：US09492422B2
公开(公告)日：2016-11-15
申请号：US13509483
申请日：2010-11-12
IPC分类号： A61K31/5585 , A61P31/10 , A61K31/343 , A61K31/4439 , A61K31/5575
CPC分类号： A61K31/343 , A61K31/4439 , A61K31/5575 , A61K2300/00
摘要： A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.
摘要翻译： 用于糖尿病的治疗或预防剂包括作为PPAR-γ激动剂的噻唑烷衍生物作为有效成分，其表现出PPAR-γ激动剂的副作用降低。 用于糖尿病的治疗或预防剂包括特定的IP激动剂如贝前列素钠（BPS）和吡咯烷衍生物如吡格列酮或其药学上可接受的盐。 由于治疗或预防剂表现出足够有效的降血糖作用，而不伴随PPAR-γ激动剂特征的副作用，因此该药剂可用作糖尿病的高度安全有效的治疗或预防剂。
-
公开(公告)号：US20120258988A1
公开(公告)日：2012-10-11
申请号：US13509483
申请日：2010-11-12
IPC分类号： A61K31/5585 , A61P3/10
CPC分类号： A61K31/343 , A61K31/4439 , A61K31/5575 , A61K2300/00
摘要： A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.
摘要翻译： 用于糖尿病的治疗或预防剂包括作为PPAR-γ激动剂的噻唑烷衍生物作为有效成分，其表现出PPAR-γ激动剂的副作用降低。 用于糖尿病的治疗或预防剂包括特定的IP激动剂如贝前列素钠（BPS）和吡咯烷衍生物如吡格列酮或其药学上可接受的盐。 由于治疗或预防剂表现出足够有效的降血糖作用，而不伴随PPAR-γ激动剂特征的副作用，因此该药剂可用作糖尿病的高度安全有效的治疗或预防剂。
-
公开(公告)号：US20060059578A1
公开(公告)日：2006-03-16
申请号：US10514716
申请日：2003-05-26
IPC分类号： A01K67/027
CPC分类号： C12N15/8509 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , A01K2267/0362 , A01K2267/0375 , C07K14/575
摘要： The animals of the present invention enable elucidation of the onset mechanisms of obesity, diabetes, and arteriosclerosis. Moreover, they are useful for screening preventive and therapeutic drugs for treating any of these diseases.
摘要翻译： 本发明的动物能够阐明肥胖，糖尿病和动脉硬化的发病机制。 此外，它们可用于筛选用于治疗任何这些疾病的预防和治疗药物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.03 秒)